कंपनी का अवलोकन
Pharming Group N.V. is a biopharmaceutical entity focused on the development and commercialization of protein replacement therapies and precision medicines designed to treat rare diseases across the United States, Europe, and international markets. The company operates within the Healthcare sector and specifically within the Biotechnology industry, a segment characterized by high research and development costs and significant regulatory hurdles before products reach the market. Its market capitalization stands at $1.14B, while its trailing twelve-month revenue is reported at $376.13M; however, specific employee count data is not available in the current records. These valuation and revenue figures indicate that the company maintains a substantial presence in the rare disease therapeutics space, yet its relatively low market cap compared to its revenue suggests a niche positioning or potential market penetration challenges typical of small-cap biotech firms. The business description highlights its lead product, RUCONEST, which serves as a recombinant C1 esterase inhibitor, indicating a specialized focus on genetic and immunological disorders rather than broad-spectrum treatments.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $376.13M, with a net income of $2.85M and an EBITDA of $43.46M. The substantial disparity between the $376.13M in revenue and the mere $2.85M in net income reveals a highly leveraged cost structure where operating expenses, likely dominated by R&D and commercialization costs for rare disease therapies, consume nearly 99% of gross profits. Despite the thin net income, the company generated $43.46M in EBITDA, suggesting that non-cash items or specific accounting treatments significantly impact the bottom line relative to operational cash generation. The free cash flow stands at $63.69M, which provides a critical buffer for financial flexibility, allowing the company to fund ongoing research programs without immediate reliance on external equity financing. Three distinct margin metrics further illustrate the financial profile: a gross margin of 87.9% indicates high pricing power or low cost of goods sold typical of biologic products, while an operating margin of 5.8% and a profit margin of 0.8% reflect the heavy investment in general and administrative expenses required to sustain clinical trials and regulatory compliance. The balance sheet shows $179.10M in cash against $115.78M in debt, resulting in a debt-to-equity ratio of 41.78, which implies a moderately leveraged but not distressed position given the strong cash reserve. A current ratio of 2.59 indicates robust short-term liquidity, ensuring the company can comfortably meet its obligations due within one year. Return on equity is calculated at 1.0% and return on assets at 4.5%, metrics that reveal management faces significant challenges in generating substantial returns on the capital deployed, a common trait in early-stage or high-growth biotechnology companies where reinvestment often dilutes immediate profitability.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is 407.75, while the forward P/E is 402.72; the negligible difference between these two figures implies that the market expects earnings to grow at a rate that closely mirrors current performance rather than anticipating a dramatic shift in profitability trajectory. The price-to-book ratio stands at 39.02, indicating a massive market premium over the company's book value, which is typical for biotech firms where intangible assets like intellectual property are not fully captured on the balance sheet but are critical to future value. Alternative valuation metrics such as the price-to-sales ratio of 3.02 and an EV/EBITDA of 247.18 suggest that investors are pricing the stock based on future revenue potential and pipeline value rather than current earnings power. The 52-week trading range spans from a low of $7.50 to a high of $21.34, providing a clear context for price volatility and historical performance boundaries. The current price metrics, while not explicitly defined as a single number in the source data, sit within this established range, reflecting the speculative nature of the asset given the high beta of 0.16. A beta of 0.16 indicates that the stock price is significantly less volatile than the broader market, moving only 16% as much as the index in a given period, which offers a unique risk profile for a high-growth biotechnology company.
Growth & Income
Pharming Group N.V. demonstrated a revenue growth rate of 14.9% year-over-year and an earnings growth rate of 98.1% year-over-year. The earnings growth rate is substantially faster than the revenue growth rate, implying significant leverage effects or one-time gains that have disproportionately boosted the bottom line compared to top-line expansion. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that it reinvests all generated earnings back into research and development, clinical trials, and commercial expansion rather than distributing cash to shareholders. This strategy is consistent with the lifecycle of a biopharmaceutical company that must prioritize asset building and regulatory approvals to realize long-term value from its pipeline. The overall growth and income profile is defined by rapid earnings acceleration supported by double-digit revenue growth, coupled with a disciplined approach to capital allocation that forgoes current income in favor of future product potential.